In particular, our result indicated that in the TCGA cohort, at a given instant in time, a glioblastoma patient exhibiting an HSC signal ≥0.54 was 88% as likely to die as someone showing an HSC signal <0.54, adjusting for age, MGMT promoter methylation and IDH mutations (Fig. 6e and Supplementary Fig. 9). The gene discussed is MGMT; the disease is glioblastoma.